Table 1.
Characteristics of the patient cohort
| |
JAK2 |
Age |
Gender |
WBC (109/L) |
Hb (g/L) |
Plt (109/L) |
Blasts (%) |
LDH (U/L) |
||
|---|---|---|---|---|---|---|---|---|---|---|
| mut | wt | m | f | |||||||
| CML (n = 10) |
0 |
10 |
55 |
9 |
1 |
81.3 |
107 |
219 |
1 |
599 |
| PV (n = 10) |
8 |
2 |
56 |
4 |
6 |
12.4 |
133 |
370 |
0 |
259 |
| ET (n = 10) |
5 |
5 |
69 |
3 |
7 |
8.2 |
130,5 |
770 |
0 |
267 |
| MF (n = 27) |
14 |
13 |
67 |
12 |
15 |
10.1 |
104,5 |
376 |
0,5 |
431 |
| Total | 27 | 30 | 66 | 28 | 29 | 11.7 | 114 | 338 | 0 | 369 |
Median values for age, WBC, Hb, Plt, Blasts, LDH. CML, Chronic myeloid leukemia, ET, essential thrombocythemia; Hb, hemoglobin; LDH, lactate dehydrogenase; MF, myelofibrosis; mut, positive for JAK2V617F; plt, platelet count; PV, polycythemiavera; WBC, white blood cell count; wt = negative for JAK2V617F.